Eli Lilly and Resilience US manufacturing expansion
The developments in this story so far, most recent first.
-
· Development
Eli Lilly and Resilience to Invest $750 Million in US Drug Manufacturing
-
· date approximate · Background
The multi-year manufacturing partnership between Eli Lilly and Resilience began.
Eli Lilly and Resilience entered a multi-year manufacturing partnership that began in 2023, according to an announcement. The collaboration has already produced more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats.
As part of the deal, the companies plan to invest $750 million to expand pharmaceutical manufacturing capacity in the US and strengthen the domestic medicine supply chain. The operations are expected to include Lilly's KwikPen injectable device for diabetes and obesity.
Edgardo Hernandez, Lilly's manufacturing head, said the partnership reflects the drugmaker's efforts to meet rising demand for its medicines. Lilly's US capital expansion commitments since 2020 total more than $55 billion, and it plans to break ground on several recently announced US manufacturing sites this year.
-
· date approximate · Background
Lilly's US capital expansion commitments began.
Eli Lilly’s commitment to expanding its domestic footprint began with substantial capital investments totaling more than $55 billion since 2020. These initiatives are designed to strengthen the internal supply chain and meet growing demands for medical treatments.
As part of this expansion, the company has planned to begin construction on several manufacturing sites within the United States in recent years.